ライフサイエンスコーパス: ALCAM

1 ALCAM [activated leukocyte cell adhesion molecule (BEN/S

2 ALCAM expression on PB and SF monocytes/macrophages is e

3 ALCAM knockdown by an ALCAM-specific siRNA significantly

4 ALCAM null mutant axons were specifically compromised in

5 ALCAM shedding, defined as detection of the intracellula

6 ALCAM significantly enhanced tube formation of endotheli

7 ALCAM supports the development of hematopoietic cells as

8 ALCAM was expressed in the SC during RGC axon targeting

9 ALCAM was expressed on monocyte-lineage cells in situ in

10 ALCAM(-/-) mice displayed an altered blood vascular netw

11 st it affected the molecular weights of HB-2/ALCAM and SR-BI/CLA-1.

12 Both RT-PCR and Western blotting for HB-2/ALCAM were negative in human fetal hepatocytes while Gp9

13 tent with patterns of expression of miR-214, ALCAM, and miR-148b in human melanoma specimens.

14 This study identifies CD166/ALCAM (ALCAM) as a close structural and functional homolog of R

15 Although ALCAM expression on tumor cells has been linked to tumor

16 ALCAM knockdown by an ALCAM-specific siRNA significantly increased cell growth

17 croRNA-192 or -215 and ALCAM knockdown by an ALCAM-specific siRNA significantly increased the migrati

18 ALCAM-negative cell line, consistent with an ALCAM-L1 heterophilic molecular interaction.

19 ested in different binding assays to analyze ALCAM-CD6 interactions in more detail.

20 ly enriched IgSF-CAMs in the VCS: NCAM-1 and ALCAM.

21 d is mediated in part by ICAM-1, VCAM-1, and ALCAM.

22 Upregulation of miR-214 and ALCAM and the loss of TFAP2 expression have been implica

23 Here, we link miR-214 and ALCAM as well as identify a core role for miR-214 in org

24 ection of mimics of microRNA-192 or -215 and ALCAM knockdown by an ALCAM-specific siRNA significantly

25 1, BFL-1 and Hemopexin among Caucasians, and ALCAM, VCAM-1, TFPI and PF-4 among Asians.

26 m of ALCAM that may have ALCAM-dependent and ALCAM-independent functions, providing further insights

27 rfering RNA show a 35% reduction in DTH, and ALCAM(-/-) RAGE(-/-) double-knockout mice show a 27% red

28 d by targeting its top-key drivers, FRZB and ALCAM in cultured human coronary artery SMCs.

29 ion of the cell adhesion molecules ITGA5 and ALCAM.

30 enchymal cells are mesodermal in origin, and ALCAM(+) submesothelial cells may be a precursor for HSC

31 Mesothelial cells expressed podoplanin and ALCAM.

32 hway involving miR-214, miR-148b, TFAP2, and ALCAM that is critical for establishing distant metastas

33 Using anti-ALCAM antibodies, submesothelial and mesothelial cells w

34 SPDEF, FOXA1, XBP1, CYB5, TFF3, NAT1, APOD, ALCAM and AR (P<0.001).

35 tinguish active LN from inactive disease are ALCAM, PF-4, properdin, and VCAM-1 among African-America

36 , as well as novel deregulated genes such as ALCAM that is prognostically relevant in MM and may iden

37 crophage colony-stimulating factor augmented ALCAM expression on PB monocytes.

38 Because ALCAM has been suggested to interact with the IgSF adhes

39 Here we show that an antibody against BEN/ALCAM/SC1/DM-GRASP/MuSC selectively labels mouse SACMNs

40 al evidence of a dynamic association between ALCAM and the actin cytoskeleton, no detailed informatio

41 sALCAM demonstrated an ability to bind ALCAM and partially inhibited ALCAM-ALCAM homophilic int

42 asensitive detection of the cancer biomarker ALCAM in serum.

43 Both ALCAM and sALCAM are expressed in a variety of cultured

44 prometastatic functions directly promoted by ALCAM.

45 nflammatory cytokine bridging RAGE and CD166/ALCAM downstream effector mechanisms, both being compens

46 Blocking CD166/ALCAM expression using small interfering RNA completely

47 This study identifies CD166/ALCAM (ALCAM) as a close structural and functional homol

48 egulation of RAGE in animals devoid of CD166/ALCAM, and vice versa.

49 and it shows that binding of S100B to CD166/ALCAM induces dose- and time-dependent expression of mem

50 ing cells through its interaction with CD166/ALCAM (activated leukocyte cell adhesion molecule), and

51 and RAGE(-/-) animals pretreated with CD166/ALCAM small interfering RNA by 50% and 40%, respectively

52 CD6-ALCAM interactions mediate immune cell adhesion and are

53 Presently, the details of CD6-ALCAM interactions and of signaling through CD6 are unkn

54 e two cell surface proteins suggest that CD6-ALCAM interactions play an important role in mediating t

55 The CD6-ALCAM (activated leukocyte cell adhesion molecule) inter

56 receptor binding domain which block the CD6-ALCAM interaction.

57 Longitudinal analysis of circulating ALCAM in tumor-bearing mice revealed that shedding of tu

58 These studies have enabled us to classify ALCAM residues according to their importance for binding

59 Consistently, ALCAM(-/-) mice, but not WT mice treated with RAGE small

60 In this study, ALCAM-deficient (ALCAM(-/-)) mice were used to evaluate the role of ALCAM

61 that shedding of tumor, but not host-derived ALCAM is elevated during growth of the cancer.

62 cancer metastasis, and neuronal development, ALCAM undergoes both homotypic interactions with other A

63 Four genes (DNAH8, ALCAM, RARS, and GBF1) also demonstrated an increase in

64 ificantly reduced for patients with elevated ALCAM shedding (P = 0.01; HR, 3.0), suggesting that ALCA

65 vial fluid (SF) macrophages, and we examined ALCAM expression in situ in RA synovium by immunofluores

66 lial-like yolk sac cells that do not express ALCAM, indicating that sALCAM has an independent effect

67 reveals a novel role of stromally expressed ALCAM in supporting tumor growth and metastatic spread.

68 sociated retinal cells and an L1-expressing, ALCAM-negative cell line, consistent with an ALCAM-L1 he

69 d with retinol, suggesting the potential for ALCAM(+) cells to differentiate to HSCs.

70 Furthermore, ALCAM expression was increased in cocaine-treated mice w

71 = 8.9 x 10-7), near the immune response gene ALCAM (3q13; P = 9.3 x 10-7), within GPC6 (13q31; P = 4.

72 novel soluble isoform of ALCAM that may have ALCAM-dependent and ALCAM-independent functions, providi

73 t the amino-terminal Ig-like domain of human ALCAM specifically binds to the third membrane-proximal

74 A series of truncated human ALCAM and CD6 immunoglobulin fusion proteins were produc

75 Experiments in ALCAM(-/-) animals displayed an only slight reduction of

76 tasis to the lungs was profoundly reduced in ALCAM(-/-) mice.

77 across species, and nonconserved residues in ALCAM and its murine homolog map to the beta-sheet face

78 The CD6 binding site in ALCAM is conserved across species, and nonconserved resi

79 creased permeability of CNS blood vessels in ALCAM KO animals.

80 for several cell surface proteins, including ALCAM/CD166, the Ephrin type A receptor, EGFR and the pr

81 Furthermore, in vitro culture-induced ALCAM expression on PB monocytes and CD14+ RA SF cells w

82 bility to bind ALCAM and partially inhibited ALCAM-ALCAM homophilic interactions.

83 Conversely, retention of intact ALCAM was associated with improved survival, thereby con

84 extracellular binding site of the CD6 ligand ALCAM, which is required for CD6 stimulation.

85 this platform, the cancer prognostic marker ALCAM could be detected in serum with a detection limit

86 on cell migration in addition to modulating ALCAM function.

87 report that that the cell adhesion molecule ALCAM (CD166) can act as an extracellular substrate to s

88 activated leukocyte cell adhesion molecule (ALCAM) and C-reactive protein (CRP) (p < 0.05), and IQR

89 activated leukocyte cell adhesion molecule (ALCAM) and platelet-derived growth factor receptor alpha

90 activated leukocyte cell adhesion molecule (ALCAM) expression at the posttranscriptional level.

91 activated leukocyte cell adhesion molecule (ALCAM) has been implicated in leukocyte transmigration a

92 activated leukocyte cell adhesion molecule (ALCAM) inhibited transmigration (P </= 0.007), and CCL21

93 Activated leukocyte cell adhesion molecule (ALCAM) is a cell adhesion molecule found on blood-brain

94 Activated leukocyte cell adhesion molecule (ALCAM) is a type I transmembrane protein member of the i

95 Activated leukocyte cell adhesion molecule (ALCAM) is expressed at the surface of epithelial ovarian

96 Activated leukocyte cell adhesion molecule (ALCAM) is expressed on various cell types, including leu

97 activated leukocyte cell adhesion molecule (ALCAM) is prognostic for outcome in patients with colore

98 activated leukocyte cell adhesion molecule (ALCAM) mediates adhesion of thymocytes to thymic epithel

99 Activated leukocyte cell adhesion molecule (ALCAM) mediates cell aggregation, which is required for

100 Activated leukocyte cell adhesion molecule (ALCAM) was recently identified as a ligand for CD6, a si

101 activated leukocyte cell adhesion molecule (ALCAM), a CD6 ligand belonging to the immunoglobulin sup

102 activated leukocyte cell adhesion molecule (ALCAM), a member of the Ig superfamily, has been detecte

103 activated leukocyte cell adhesion molecule (ALCAM), a model cancer biomarker, in undiluted serum wit

104 activated leukocyte cell adhesion molecule (ALCAM), is actively shed from metastatic prostate cancer

105 -activated leukocyte cell adhesion molecule (ALCAM/CD166).

106 activated leukocyte cell adhesion molecule [ALCAM]) is a marker of colorectal cancer (CRC) stem cell

107 crophages showed that the adhesion molecules ALCAM, ICAM4, and Syndecan-2, as well as macrophage adhe

108 usion proteins containing single or multiple ALCAM or CD6 domains, we were able to determine that the

109 d/tested in four or more papers each, namely ALCAM, CCL2 (MCP1), CD163, HAVCR1 (KIM-1), HPGDS, ICAM-1

110 ion of ICAM-1+ mature/activated neutrophils, ALCAM+ monocytes, and CD38+CD8+ T cells).

111 A total of ten new ALCAM mutants were prepared, and three additional residu

112 The absence of ALCAM expression in cells forming the stromal tumor micr

113 d in active EAE was linked to the absence of ALCAM on BBB-ECs.

114 from brain tissue demonstrate association of ALCAM, ARAP1, GPC6, and RBFOX1 with brain B-amyloid load

115 n and metastatic spread, the contribution of ALCAM expressed in cells forming the tumor stroma to can

116 r the first time the in vivo contribution of ALCAM to angiogenesis and reveals a novel role of stroma

117 the single amino-terminal Ig-like domain of ALCAM and lacks a transmembrane domain.

118 ain cultures, the growth-promoting effect of ALCAM was abolished by neutralizing antibodies for compo

119 sALCAM completely abolished these effects of ALCAM.

120 ) pathways resulted in induced expression of ALCAM.

121 es mapped to the predicted A'GFCC'C" face of ALCAM's N-terminal domain.

122 oint to a biologically important function of ALCAM in maintaining BBB integrity.

123 The reduced growth of ALCAM knockdown cells corresponded to an increase in apo

124 f RGC axons from the temporal retina half of ALCAM null mice to abnormally lateral sites in the contr

125 ings implicate cocaine-mediated induction of ALCAM as a mediator of increased monocyte adhesion/trans

126 Cocaine-mediated induction of ALCAM in human brain microvascular endothelial cells thr

127 Here, we isolated a novel soluble isoform of ALCAM (sALCAM) that is produced via alternative splicing

128 data characterize a novel soluble isoform of ALCAM that may have ALCAM-dependent and ALCAM-independen

129 Gene-specific knockdown of ALCAM in bone-metastatic PC3 cells greatly diminished bo

130 In addition, expression levels of ALCAM were significantly lower in GC than in NS.

131 ly is this posttranslational modification of ALCAM a marker of prostate cancer progression, the molec

132 Targeted mutagenesis of ALCAM reveals that residues which constitute the CD6 bin

133 The extracellular region of ALCAM includes five Ig-like domains, and its N-terminal

134 olled by TFAP2), both negative regulators of ALCAM.

135 -/-)) mice were used to evaluate the role of ALCAM in lung tumor growth and metastasis.

136 d controls, suggesting the important role of ALCAM in promoting leukocyte infiltration across the BBB

137 M, lending additional support to the role of ALCAM.

138 We now show that upregulation of ALCAM in the brain endothelium seen in HIV(+)/cocaine dr

139 This study clarifies the prognostic value of ALCAM by visualizing ectodomain shedding using a dual st

140 Previous reports on the prognostic value of ALCAM expression in CRC have been contradictory and inco

141 Mice deficient in NCAM-1, but not CNTN2 or ALCAM, exhibited defects in PC gene expression and VCS p

142 ive correlation between miR-214 and ITGA5 or ALCAM along with an inverse correlation of miR-214 and m

143 be overridden by overexpression of ITGA5 or ALCAM in the same tumor cells.

144 compare the contribution of these and other ALCAM residues to the CD6-ligand interaction.

145 rgoes both homotypic interactions with other ALCAM molecules and heterotypic interactions with the su

146 ing the mobilization of the adhesion protein ALCAM to the lipid rafts of the tumor cell membrane thro

147 resent in rheumatoid synovium could regulate ALCAM cell surface expression on peripheral blood (PB) m

148 Silencing ALCAM in miR-214-overexpressing melanoma cells reduced c

149 Previously, six ALCAM residues were identified by alanine scanning mutag

150 In this study, ALCAM-deficient (ALCAM(-/-)) mice were used to evaluate

151 As a substrate, ALCAM-Fc protein promoted L1-dependent attachment of acu

152 f the interaction between the amino-terminal ALCAM domains and the membrane-proximal CD6 SRCR domain

153 vitro, and molecular analysis confirmed that ALCAM is associated with tight junction molecule assembl

154 h improved survival, thereby confirming that ALCAM shedding is associated with poor patient outcome.

155 In the present study, we found that ALCAM knockout (KO) mice developed a more severe myelin

156 tinocollicular mapping, we hypothesized that ALCAM might direct topographic targeting to the superior

157 s of prostate cancer cell lines reveals that ALCAM expression and shedding is elevated in response to

158 hedding (P = 0.01; HR, 3.0), suggesting that ALCAM shedding can identify patients with early-stage di

159 The ALCAM substrate was also found to modulate the response

160 The ALCAM(+) cells expressed hepatocyte growth factor and pl

161 The ALCAM(+) cells formed intracellular lipid droplets when

162 In culture, the ALCAM(+) cells rapidly acquired myofibroblastic morpholo

163 rk to understand the stabilizing role of the ALCAM supramolecular complex engaged to CD6 during dendr

164 Together, these data demonstrate that the ALCAM is both a functional regulator as well as marker o

165 Neutralizing antibody to ALCAM ameliorated this effect.

166 retreating with the neutralizing antibody to ALCAM, lending additional support to the role of ALCAM.

167 , phenotypic characterization of unimmunized ALCAM KO mice revealed a reduced expression of BBB junct

168 miR-214 upregulated ALCAM, acting transcriptionally through TFAP2 and also p

169 Functional implication of upregulated ALCAM was confirmed using cell adhesion and transmigrati

170 and-independent supramolecular complex where ALCAM stably interacts with actin by binding to syntenin

171 ther, these results suggest a model in which ALCAM in the SC interacts with L1 on RGC axons to promot